HealthCare Global Enterprises Ltd (NSE:HCG) reported a robust start to fiscal year 2027, outlining a clear path toward significant EBITDA margin expansion and sustained revenue growth during its Q1 earnings call.
Strategic Roadmap for EBITDA Margin Expansion
CEO Dr. Manish Mattu confirmed that HCG is targeting EBITDA margins of 21-22% within the next two years, with an ambitious goal of reaching 24-25% over the next four to five years. Key drivers for this trajectory include a 200-basis-point improvement in the payer mix this quarter, heavy investment in clinical technologies—such as surgical robots, tomotherapy, and MR-Linac—and the strategic onboarding of 20 specialized oncologists in recent months. Furthermore, the maturation of existing centers and reduced losses at the North Bangalore facility are expected to bolster bottom-line performance.
Managing Portfolio Shifts and Revenue Quality
HCG intentionally discontinued certain high-value but low-margin chemotherapy drugs, a move that impacted Q1 FY27 top-line growth by 1.5%. Management noted that this decision is margin-accretive. The impact of this shift is expected to persist for the next two quarters before tapering off as the company replaces that volume with higher-margin cash and non-institutional business.
North Bangalore Performance and Operational Milestones
The newly commissioned North Bangalore hospital is gaining momentum, recording 550 new patient registrations and over 300 admissions in Q1 FY27, contributing INR 67 million in revenue. While the facility is currently in its investment phase, leadership expects peak EBITDA losses to have occurred this quarter. CFO Sanjeev Kumar projects monthly break-even within the current fiscal year, with optimal utilization of 60-65% anticipated by the third or fourth year of operation.
Revenue Bucket Evolution
The company’s hospital portfolio is demonstrating clear upward mobility. The number of hospitals generating over INR 10 crore per month has increased from four to seven. Simultaneously, the mid-tier category (INR 5-10 crore monthly revenue) saw a decrease from 14 to 11 facilities, signaling that these units have successfully transitioned into higher revenue brackets. The <5 crore category grew slightly to seven, primarily due to the addition of the new North Bangalore site.
Financial Discipline and CapEx Strategy
HCG is actively optimizing its balance sheet. Following a rights issue, the company utilized INR 170 crore to reduce debt, resulting in lower interest costs this quarter. CFO Sanjeev Kumar emphasized that future growth will be funded through a balanced mix of debt and internal equity. Regarding capital expenditure, HCG spent approximately INR 750 million in Q1 FY27, split between INR 350 million for growth and INR 400 million for maintenance, with annual maintenance CapEx projected at INR 100 crore.
Future Outlook: Technology and Market Positioning
Dr. Mattu reaffirmed the company’s commitment to mid-teens revenue growth, fueled by an 8% CAGR in bed expansion, same-center growth, and an improved clinical case mix. By integrating advanced therapies—including CAR-T cell therapy, bone marrow transplants, and theranostics—HCG aims to handle increasingly complex oncology cases. Marketing expenditure, currently at 2.9% of sales due to the North Bangalore launch, is expected to stabilize at 2.5-2.6% in the long term to maintain competitiveness.